CClinicalTrials.gg
CompletedNCT04026685NICOM-USBUpdated Feb 17, 2021

Maternal Haemodynamic Changes After Crystalloid Co-loading and Phenylephrine Versus Phenylephrine Alone During Spinal Anaesthesia for Elective Caesarean Delivery

An interventional study of Phenylephrine infusion and Phenylephrine infusion and Ringer-Acetate bolus in Maternal Haemodynamic Stability, sponsored by University Hospital, Basel, Switzerland. Completed at 1 site in Switzerland. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-17.

Sponsored by University Hospital, Basel, Switzerland · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Spinal anaesthesia is the anaesthetic technique of choice for elective caesarean delivery. Hypotension, a result of the decrease in systemic vascular resistance caused by spinal anaesthesia, is a frequent complication occurring in up to 80%. This study is to investigate fluid loading plus vasopressors to vasopressors alone to maintain stable maternal haemodynamics in elective caesarean delivery. The effect of the two methods (continuous prophylactic phenylephrine infusion with and without crystalloid co-loading) on maternal haemodynamics will be compared using the Starling SV Monitor. The Starling SV device is a non invasive cardiac output monitor (NICOM) which is certified and validated for the use in pregnancy.

02

Conditions studied

  • Maternal Haemodynamic Stability

Keywords

  • caesarean delivery
  • phenylephrine
  • spinal anaesthesia
  • vasopressor administration
  • pregnancy
  • non invasive cardiac output (CO) monitoring (NICOM)
03

In context

Lead sponsor

University Hospital, Basel, Switzerland is the lead sponsor of 968 studies on the registry; 191 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Ability to give informed consent
  • Term uncomplicated singleton pregnancy
  • Undergoing elective caesarean section under spinal anaesthesia
  • Weight: 50-100kg
  • Height: 150-180cm
  • Healthy term fetus

Exclusion criteria

Exclusion Criteria:

  • Inability to give informed consent
  • Multiple pregnancy
  • Clinically significant concomitant disease states (e.g. hypertension, cardiac disease, severe asthma requiring regular medication, comorbidities affecting the autonomous nervous system, renal disease)
  • On any cardiovascular medication
  • Complications of pregnancy (e.g. preeclampsia, intrauterine growth restriction, fetal malformations)
  • Known or suspected non-compliance, drug or alcohol abuse
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia of the participant,
  • Participation in another study with investigational drug within the 30 days preceding and during the present study,
  • Previous enrolment into the current study,
  • Enrolment of the investigator, his/her family members, employees and other dependent persons
  • Any fetal pathology (e.g. fetal malformations, rupture of membranes before caesarean section, oligohydramnios, polyhydramnios, suspected chorioamnionitis)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
66 participants (actual)

Study arms

  • Active comparator
    Phenylephrine infusion only

    Phenylephrine infusion only

    Drug: Phenylephrine infusion

  • Active comparator
    Phenylephrine infusion and Ringer-Acetate bolus

    Phenylephrine infusion and Ringer-Acetate bolus

    Drug: Phenylephrine infusion and Ringer-Acetate bolus

Interventions

  • DrugPhenylephrine infusion

    continuous phenylephrine infusion started at a rate of 25mcg/min and titrated according to blood pressure

  • DrugPhenylephrine infusion and Ringer-Acetate bolus

    continuous phenylephrine infusion started at a rate of 25mcg/min and titrated according to blood pressure plus crystalloid Ringer-Acetate co-loading bolus of 1000 mL

06

What researchers measure

Primary outcomes

  1. Change in maternal cardiac output (CO)

    CO measured by area under the curve (AUC) (L/min.)

    Time frame: measured every minute after induction of spinal anaesthesia (=baseline) until 5 minutes after cord clamping

Secondary outcomes

  1. Change in maternal heart rate

    Change in maternal heart rate

    Time frame: measured every minute after induction of spinal anaesthesia (=baseline) until 5 minutes after cord clamping

  2. Change in maternal diastolic and systolic blood pressure

    Change in maternal diastolic and systolic blood pressure (mmHg)

    Time frame: measured every minute after induction of spinal anaesthesia (=baseline) until 5 minutes after cord clamping

  3. incidence of maternal nausea

    incidence of maternal Nausea (number)

    Time frame: measured every minute after induction of spinal anaesthesia (=baseline) until 5 minutes after cord clamping

  4. Change in Apgar scores

    The Apgar score is determined by evaluating the newborn baby on five simple criteria on a scale from zero to two, then summing up the five values thus obtained. The resulting Apgar score ranges from zero to 10. The five criteria are summarized using words chosen to form a backronym (Appearance, Pulse, Grimace, Activity, Respiration).

    Time frame: at 1 and 5 minutes after delivery

  5. Change in umbilical cord pH

    Change in umbilical cord pH

    Time frame: at 1 and 5 minutes after delivery

07

Study locations

1 site
  • Department of Anaesthesiology, University Hospital of Basel (USB)
    Basel, 4031, Switzerland
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04026685
Lead sponsor
University Hospital, Basel, Switzerland
Responsible party
Sponsor
First posted
Jul 19, 2019
Start date
Jan 9, 2020
Primary completion
Feb 5, 2021
Completion
Feb 5, 2021
Last update
Feb 17, 2021

Study contacts

Bigna Buddeberg, Dr. med
principal investigator · Department of Anaesthesiology, University Hospital of Basel

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion